Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?

Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?

Show other versions (1)

Bibliographic Details
Main Authors:	Nader I. Al-Dewik, Hisham M. Morsi, Muthanna M. Samara, Rola S. Ghasoub, Cinquea C. Gnanam, Subi K. Bhaskaran, Abdulqadir J. Nashwan, Rana M. Al-Jurf, Mohamed A. Ismail, Mohammed M. AlSharshani, Ali A. AlSayab, Tawfeg I. Ben-Omran, Rani B. Khatib, Mohamed A. Yassin
Format:	Article
Language:	English
Published:	SAGE Publishing 2016-10-01
Series:	Clinical Medicine Insights: Oncology
Online Access:	http://www.la-press.com/is-adherence-to-imatinib-mesylate-treatment-among-patients-with-chroni-article-a5939

Similar Items

Is Adherence to Imatinib Mesylate Treatment among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?
by: Nader I. Al-Dewik, et al.
Published: (2016-01-01)

Aberrant DNA methylation of PTPRG as one possible mechanism of its under‐expression in CML patients in the State of Qatar
by: Mohamed A. Ismail, et al.
Published: (2020-10-01)

Effects of consanguinity in a cohort of subjects with certain genetic disorders in Qatar
by: Tawfeg Ben‐Omran, et al.
Published: (2020-01-01)

The teratogenic effects of imatinib mesylate on rat fetuses
by: M.M. El Gendy, et al.
Published: (2015-01-01)

Periorbital edema secondary to imatinib mesylate
by: Collin M McClelland, et al.
Published: (2010-05-01)

Renal phosphate loss in Iraqi chronic myeloid leukemia patients treated by imatinib mesylate
by: Huda A Al-Taee, et al.
Published: (2020-01-01)

Imatinibe mesilato no Brasil Imatinibe mesylate in Brazil
by: Marcos Lima
Published: (2005-09-01)

Imatinib mesylate-induced palmoplantar keratoderma
by: Niharika Jha, et al.
Published: (2021-01-01)

Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate
by: Bożena Karolewicz, et al.
Published: (2019-07-01)

A Case of Chronic Neutrophilic Leukemia Successfully Treated with Pegylated Interferon Alpha-2a
by: Mohamed A. Yassin, et al.
Published: (2015-01-01)

A Case of Chronic Neutrophilic Leukemia Successfully Treated with Pegylated Interferon Alpha-2a
by: Mohamed A. Yassin, et al.
Published: (2015-04-01)

Formulation and characterization of novel soft nanovesicles for enhanced transdermal delivery of eprosartan mesylate
by: Abdul Ahad, et al.
Published: (2017-11-01)

Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity
by: İshak Suat Övey, et al.
Published: (2020-03-01)

Mutations Associated with Imatinib Mesylate Resistance - Review
by: Linev Alexandar J., et al.
Published: (2018-12-01)

Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia
by: G.A.P. Oliveira, et al.
Published: (2010-06-01)

Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients
by: Mohamed A. Ismail, et al.
Published: (2021-04-01)

Genomics and Precision Medicine: Molecular Diagnostics Innovations Shaping the Future of Healthcare in Qatar
by: Nader I. AL-Dewik, et al.
Published: (2019-01-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-09-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-07-01)

The role of c-kit and imatinib mesylate in uveal melanoma
by: Pereira Patricia, et al.
Published: (2005-10-01)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
by: Omar S Din, et al.
Published: (2008-03-01)

An ESP Program Model for Graduate Students at King Saud University Based on Academic and Occupational Needs
by: Reema Al-Jurf
Published: (1994-01-01)

An ESP Program Model for Graduate Students at King Saud University Based on Academic and Occupational Needs
by: Reema Al-Jurf
Published: (1994-01-01)

A rare complication of imatinib mesylate therapy: drug-induced pneumonitis
by: Ol'ga Veniaminovna Stakhina, et al.
Published: (2010-02-01)

In vitro inhibitory effects of imatinib mesylate on stromal cells and hematopoietic progenitors from bone marrow
by: P.B. Soares, et al.
Published: (2013-01-01)

ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor.
by: Lori Rink, et al.
Published: (2013-01-01)

Generalized lichenoid drug eruption associated with imatinib mesylate therapy
by: Sudip Kumar Ghosh
Published: (2013-01-01)

OUR EXPERIENCE WITH TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Mojca Modic, et al.
Published: (2004-12-01)

Anti-Diabetic and Beta-Cell Protective Actions of Imatinib Mesylate
by: Hägerkvist, Robert
Published: (2006)

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
by: Alexandra Rodrigues Alves, et al.

OUR EXPERIENCE IN TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Marjana Glaser, et al.
Published: (2004-04-01)

Column chromatography USED in purification of genotoxic impurity sample of imatinib mesylate substance
by: V. I. Krylov, et al.
Published: (2018-02-01)

Formulation and in vitro, in vivo evaluation of effervescent floating sustained-release imatinib mesylate tablet.
by: Ali Kadivar, et al.
Published: (2015-01-01)

Effects of imatinib mesylate on cutaneous neurofibromas associated with neurofibromatosis type 1
by: Ken‐ichi Yasuda, et al.
Published: (2020-11-01)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
by: Vijay Gandhi Linga, et al.
Published: (2014-01-01)

Effects of Imatinib Mesylate in Mouse Models of Multiple Sclerosis and In vitro Determinants
by: Gholamreza Azizi, et al.
Published: (2014-06-01)

Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia
by: Aamer Aleem
Published: (2009-04-01)

Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.
by: Zheng Hu, et al.
Published: (2009-01-01)

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
by: Ruth Gauden, et al.
Published: (2011-04-01)

Imatinib mesylate-induced cutaneous rash masquerading as pityriasis rosea of Gilbert
by: Prashant Verma, et al.
Published: (2014-01-01)